122 related articles for article (PubMed ID: 30682105)
61. Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer.
Lu J; Xu Y; Wu Y; Huang XY; Xie JW; Wang JB; Lin JX; Li P; Zheng CH; Huang AM; Huang CM
BMC Cancer; 2019 Sep; 19(1):920. PubMed ID: 31521128
[TBL] [Abstract][Full Text] [Related]
62. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
63. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
Liang Y; Lü W; Zhang X; Lü B
Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
[TBL] [Abstract][Full Text] [Related]
64. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1
Moreno-Cubero E; Subirá D; Sanz-de-Villalobos E; Parra-Cid T; Madejón A; Miquel J; Olveira A; González-Praetorius A; García-Samaniego J; Larrubia JR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093082
[TBL] [Abstract][Full Text] [Related]
65. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
[TBL] [Abstract][Full Text] [Related]
66. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
[TBL] [Abstract][Full Text] [Related]
67. Tumor-infiltrating lymphocytes and CD8
Vihervuori H; Autere TA; Repo H; Kurki S; Kallio L; Lintunen MM; Talvinen K; Kronqvist P
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3105-3114. PubMed ID: 31562550
[TBL] [Abstract][Full Text] [Related]
68. Prognostic Values of CD38
Zhang M; Yang J; Zhou J; Gao W; Zhang Y; Lin Y; Wang H; Ruan Z; Ni B
Immunol Invest; 2019 Jul; 48(5):466-479. PubMed ID: 30689488
[TBL] [Abstract][Full Text] [Related]
69. Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy.
Mauzo SH; Tetzlaff MT; Milton DR; Siroy AE; Nagarajan P; Torres-Cabala CA; Ivan D; Curry JL; Hudgens CW; Wargo JA; Sahin AA; Pettaway CA; Prieto VG; Aung PP
Cancers (Basel); 2019 May; 11(6):. PubMed ID: 31146499
[TBL] [Abstract][Full Text] [Related]
70. The Warburg effect and tumour immune microenvironment in extramammary Paget's disease: overexpression of lactate dehydrogenase A correlates with immune resistance.
Urata K; Kajihara I; Miyauchi H; Mijiddorj T; Otsuka-Maeda S; Sakamoto R; Sawamura S; Kanemaru H; Kanazawa-Yamada S; Makino K; Aoi J; Makino T; Fukushima S; Komohara Y; Ihn H
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1715-1721. PubMed ID: 31838771
[TBL] [Abstract][Full Text] [Related]
71. [Establishment of culture system for selective amplification of CD8
Liu J; Mao C; Ye F; Yuan X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Apr; 39(4):311-317. PubMed ID: 37087548
[TBL] [Abstract][Full Text] [Related]
72. Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease.
Goto H; Sugita K; Yamamoto O
Indian J Dermatol; 2021; 66(2):169-173. PubMed ID: 34188273
[TBL] [Abstract][Full Text] [Related]
73. Relationship Between CD8+ T Cells and Prognosis of Esophageal Cancer Patients: A Systematic Review and Meta-analysis.
Liu B; Liu Z; Gao C
Mol Biotechnol; 2024 Jan; 66(1):138-150. PubMed ID: 37060513
[TBL] [Abstract][Full Text] [Related]
74. Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8
Hanoteau A; Henin C; Svec D; Bisilliat Donnet C; Denanglaire S; Colau D; Romero P; Leo O; Van den Eynde B; Moser M
Oncoimmunology; 2017; 6(8):e1318234. PubMed ID: 28919989
[TBL] [Abstract][Full Text] [Related]
75. Pathologically Confirmed Subcutaneous Fat and Lymphovascular Invasion of a Hypopigmented Area in Extramammary Paget Disease.
Huh G; Lee GY; Chung Y; Chae SW; Choi YJ
Ann Dermatol; 2023 Nov; 35(Suppl 2):S229-S233. PubMed ID: 38061710
[TBL] [Abstract][Full Text] [Related]
76. Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer.
Wu Y; Yu S; Qiao H
Front Pharmacol; 2022; 13():990445. PubMed ID: 36120342
[TBL] [Abstract][Full Text] [Related]
77. Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers.
Fujimura T
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409404
[TBL] [Abstract][Full Text] [Related]
78. T Cell Immune Profiles of Blood and Tumor in Dogs Diagnosed With Malignant Melanoma.
Sparger EE; Chang H; Chin N; Rebhun RB; Withers SS; Kieu H; Canter RJ; Monjazeb AM; Kent MS
Front Vet Sci; 2021; 8():772932. PubMed ID: 34926643
[TBL] [Abstract][Full Text] [Related]
79. The unfolded protein response links tumor aneuploidy to local immune dysregulation.
Xian S; Dosset M; Almanza G; Searles S; Sahani P; Waller TC; Jepsen K; Carter H; Zanetti M
EMBO Rep; 2021 Dec; 22(12):e52509. PubMed ID: 34698427
[TBL] [Abstract][Full Text] [Related]
80. The Msi1-mTOR pathway drives the pathogenesis of mammary and extramammary Paget's disease.
Song Y; Guerrero-Juarez CF; Chen Z; Tang Y; Ma X; Lv C; Bi X; Deng M; Bu L; Tian Y; Liu R; Zhao R; Xu J; Sheng X; Du S; Liu Y; Zhu Y; Shan SJ; Chen HD; Zhao Y; Zhou G; Shuai J; Ren F; Xue L; Ying Z; Dai X; Lengner CJ; Andersen B; Plikus MV; Nie Q; Yu Z
Cell Res; 2020 Oct; 30(10):854-872. PubMed ID: 32457396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
